In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease

Journal of Virology

Volumn 88, Issue 9, 2014, Pages 5087-5099

  Althof, Nadine ^a   Harkins, Stephanie ^a   Kemball, Christopher C ^a   Flynn, Claudia T ^a   Alirezaei, Mehrdad ^a   Whitton, Lindsay J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; INTERFERON RECEPTOR; TYPE I INTERFERON RECEPTOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; DISEASE EXACERBATION; ENZYME ACTIVITY; GENE DELETION; HEART MUSCLE CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; MYOCARDIAL DISEASE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR GENE; TYPE I INTERFERON RECEPTOR GENE; VIRAL CLEARANCE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS TRANSMISSION;

ANIMALS; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDITIS; MYOCYTES, CARDIAC; RECEPTOR, INTERFERON ALPHA-BETA; SURVIVAL ANALYSIS;

EID: 84897560377     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00184-14     Document Type: Article

References (99)

1. Magnani JW, Dec GW. 2006. Myocarditis: current trends in diagnosis and treatment. Circulation 113:876-890. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.584532.
2. Esfandiarei M, McManus BM. 2008. Molecular biology and pathogenesis of viral myocarditis. Annu. Rev. Pathol. 3:127-155. http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.151534.
3. Marchant D, Si X, Luo H, McManus B, Yang D. 2008. The impact of CVB3 infection on host cell biology. Curr. Top. Microbiol. Immunol. 323:177-198. http://dx.doi.org/10.1007/978-3-540-75546-3_8.
4. Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. 2009. Viral causes of human myocarditis. Arch. Cardiovasc. Dis. 102:559-568. http://dx.doi.org/10.1016/j.acvd.2009.04.010.
5. Mahfoud F, Gartner B, Kindermann M, Ukena C, Gadomski K, Klingel K, Kandolf R, Bohm M, Kindermann I. 2011. Virus serology in patients with suspected myocarditis: utility or futility? Eur. Heart J. 32:897-903. http://dx.doi.org/10.1093/eurheartj/ehq493.
6. Blauwet LA, Cooper LT. 2010. Myocarditis. Prog. Cardiovasc. Dis. 52: 274-288. http://dx.doi.org/10.1016/j.pcad.2009.11.006.
7. Sagar S, Liu PP, Cooper LT, Jr. 2012. Myocarditis. Lancet 379:738-747. http://dx.doi.org/10.1016/S0140-6736(11)60648-X.
8. Corsten MF, Schroen B, Heymans S. 2012. Inflammation in viral myocarditis: friend or foe? Trends Mol. Med. 18:426-437. http://dx.doi.org/10.1016/j.molmed.2012.05.005.
9. Wakafuji S, Okada R. 1986. Twenty year autopsy statistics of myocarditis incidence in Japan. Jpn. Circ. J. 50:1288-1293. http://dx.doi.org/10.1253/jcj.50.1288.
10. Gravanis MB, Sternby NH. 1991. Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch. Pathol. Lab. Med. 115:390-392.
11. Carniel E, Sinagra G, Bussani R, Di Lenarda A, Pinamonti B, Lardieri G, Silvestri F. 2004. Fatal myocarditis: morphologic and clinical features. Ital. Heart J. 5:702-706.
12. Ward C. 1978. Severe arrhythmias in coxsackievirus B3 myopericarditis. Arch. Dis. Child. 53:174-176. http://dx.doi.org/10.1136/adc.53.2.174.
13. Bendig JWA, O'Brien PS, Muir P, Porter HJ, Caul EO. 2001. Enterovirus sequences resembling coxsackievirus A2 detected in stool and spleen from a girl with fatal myocarditis. J. Med. Virol. 64:482-486. http://dx.doi.org/10.1002/jmv.1075.
14. Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, Pearse LA, Virmani R. 2004. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann. Intern. Med. 141:829-834. http://dx.doi.org/10.7326/0003-4819-141-11-200412070-00005.
15. O'Connell JB. 1987. The role of myocarditis in end-stage dilated cardiomyopathy. Tex. Heart Inst. J. 14:268-275.
16. Sole MJ, Liu P. 1993. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J. Am. Coll. Cardiol. 22:99A-105A. http://dx.doi.org/10.1016/0735-1097(93)90470-L.
17. Riecansky I, Schreinerova Z, Egnerova A, Petrovicova A, Bzduchova O. 1989. Incidence of coxsackie virus infection in patients with dilated cardiomyopathy. Cor Vasa 31:225-230.
18. Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. 2005. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 111:887-893. http://dx.doi.org/10.1161/01.CIR.0000155616.07901.35.
19. Archard LC, Bowles NE, Cunningham L, Freeke CA, Olsen EG, Rose ML, Meany B, Why HJ, Richardson PJ. 1991. Molecular probes for detection of persisting enterovirus infection of human heart and their prognostic value. Eur. Heart J. 12(Suppl D):56-59. http://dx.doi.org/10.1093/eurheartj/12.suppl_D.56.
20. Heim A, Canu A, Kirschner P, Simon T, Mall G, Hofschneider PH, Kandolf R. 1992. Synergistic interaction of interferon-β and interferon-γ in coxsackievirus B3-infected carrier cultures of human myocardial fibroblasts. J. Infect. Dis. 166:958-965. http://dx.doi.org/10.1093/infdis/166.5.985.
21. Kandolf R, Canu A, Hofschneider PH. 1985. Coxsackie B3 virus can replicate in cultured human foetal heart cells and is inhibited by interferon. J. Mol. Cell. Cardiol. 17:167-181. http://dx.doi.org/10.1016/S0022-2828(85)80019-5.
22. Hofschneider PH, Klingel K, Kandolf R. 1990. Toward understanding the pathogenesis of enterovirus-induced cardiomyopathy: molecular and ultrastructural approaches. J. Struct. Biol. 104:32-37. http://dx.doi.org/10.1016/1047-8477(90)90054-G.
23. Klingel K, Kandolf R. 1993. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand. J. Infect. Dis. Suppl. 88:79-85.
24. Gomez RM, Lopez Costa JJ, Pecci Saavedra G, Berria MI. 1993. Ultrastructural study of cell injury induced by coxsackievirus B3 in pancreatic and cardiac tissues. Medicina (B. Aires) 53:300-306.
25. Herzum M, Ruppert V, Kuytz B, Jomaa H, Nakamura I, Maisch B. 1994. Coxsackievirus B3 infection leads to cell death of cardiac myocytes. J. Mol. Cell. Cardiol. 26:907-913. http://dx.doi.org/10.1006/jmcc.1994.1108.
26. Kallewaard NL, Zhang L, Chen JW, Guttenberg M, Sanchez MD, Bergelson JM. 2009. Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis. Cell Host Microbe 6:91-98. http://dx.doi.org/10.1016/j.chom.2009.05.018.
27. Shi Y, Chen C, Lisewski U, Wrackmeyer U, Radke M, Westermann D, Sauter M, Tschope C, Poller W, Klingel K, Gotthardt M. 2009. Cardiac deletion of the coxsackievirus-adenovirus receptor abolishes coxsackievirus B3 infection and prevents myocarditis in vivo. J. Am. Coll. Cardiol. 53:1219-1226. http://dx.doi.org/10.1016/j.jacc.2008.10.064.
28. Huber S, Sartini D. 2005. T cells expressing the Vγ1 T-cell receptor enhance virus-neutralizing antibody response during coxsackievirus B3 infection of BALB/c mice: differences in male and female mice. Viral Immunol. 18:730-739. http://dx.doi.org/10.1089/vim.2005.18.730.
29. Woodruff JF, Woodruff JJ. 1974. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J. Immunol. 113:1726-1734.
30. Hashimoto I, Tatsumi M, Nakagawa M. 1983. The role of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. Br. J. Exp. Pathol. 64:497-504.
31. Ytterberg SR, Mahowald ML, Messner RP. 1988. T cells are required for coxsackievirus B1 induced murine polymyositis. J. Rheumatol. 15:475-478.
32. Kishimoto C, Abelmann WH. 1990. In vivo significance of T cells in the development of coxsackievirus B3 myocarditis in mice. Immature but antigen-specific T cells aggravate cardiac injury. Circ. Res. 67:589-598.
33. + T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 69:6720-6728.
34. Huber SA. 2006. Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimmunity 39:55-61. http://dx.doi.org/10.1080/08916930500484906.
35. Huber S, Song WC, Sartini D. 2006. Decay-accelerating factor (CD55) promotes CD1d expression and Vγ4+ T-cell activation in coxsackievirus B3-induced myocarditis. Viral Immunol. 19:156-166. http://dx.doi.org/10.1089/vim.2006.19.156.
36. + cells. Microbes Infect. 7:537-543. http://dx.doi.org/10.1016/j.micinf.2004.12.011.
37. Gauntt CJ, Higdon AL, Arizpe HM, Tamayo MR, Crawley R, Henkel RD, Pereira ME, Tracy SM, Cunningham MW. 1993. Epitopes shared between coxsackievirus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis. Clin. Immunol. Immunopathol. 68: 129-134. http://dx.doi.org/10.1006/clin.1993.1108.
38. Gauntt CJ, Arizpe HM, Higdon AL, Wood HJ, Bowers DF, Rozek MM, Crawley R. 1995. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis. J. Immunol. 154:2983-2995.
39. Chow LH, Beisel KW, McManus BM. 1992. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab. Invest. 66:24-31.
40. Mena I, Perry CM, Harkins S, Rodriguez F, Gebhard JR, Whitton JL. 1999. The role of B lymphocytes in coxsackievirus B3 infection. Am. J. Pathol. 155: 1205-1215. http://dx.doi.org/10.1016/S0002-9440(10)65223-6.
41. Wessely R, Klingel K, Knowlton KU, Kandolf R. 2001. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation 103: 756-761. http://dx.doi.org/10.1161/01.CIR.103.5.756.
42. Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN. 2004. Protective role for interferon-β in coxsackievirus B3 infection. Circulation 110:3540-3543. http://dx.doi.org/10.1161/01.CIR.0000136824.73458.20.
43. 2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am. J. Physiol. Heart Circ. Physiol. 293:H69-H76. http://dx.doi.org/10.1152/ajpheart.00154.2007.
44. Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP. 2003. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793-2798. http://dx.doi.org/10.1161/01.CIR.0000072766.67150.51.
45. Kuhl U, Lassner D, von Schlippenbach J, Poller W, Schultheiss HP. 2012. Interferon-β improves survival in enterovirus-associated cardiomyopathy. J. Am. Coll. Cardiol. 60:1295-1296. http://dx.doi.org/10.1016/j.jacc.2012.06.026.
46. Yasukawa H, Yajima T, Duplain H, Iwatate M, Kido M, Hoshijima M, Weitzman MD, Nakamura T, Woodard S, Xiong D, Yoshimura A, Chien KR, Knowlton KU. 2003. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111:469-478. http://dx.doi.org/10.1172/JCI16491.
47. Yajima T, Yasukawa H, Jeon ES, Xiong D, Dorner A, Iwatate M, Nara M, Zhou H, Summers-Torres D, Hoshijima M, Chien KR, Yoshimura A, Knowlton KU. 2006. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 114:2364-2373. http://dx.doi.org/10.1161/CIRCULATIONAHA.106.642454.
48. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. 2006. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108:3253-3261. http://dx.doi.org/10.1182/blood-2006-06-027599.
49. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD. 2001. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ. Res. 89:20-25. http://dx.doi.org/10.1161/hh1301.092687.
50. Muller U, Steinhoff U, Reis LFL, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-1921. http://dx.doi.org/10.1126/science.8009221.
51. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilcek J, Zinkernagel RM, Aguet M. 1993. Immune response in mice that lack the interferon-γ receptor. Science 259:1742-1745. http://dx.doi.org/10.1126/science.8456301.
52. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG. 1993. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol. Endocrinol. 7:232-240. http://dx.doi.org/10.1210/mend.7.2.8469236.
53. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1686-1690. http://dx.doi.org/10.1093/nar/23.10.1686.
54. Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M. 1996. Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res. 24:543-548. http://dx.doi.org/10.1093/nar/24.4.543.
55. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. 2007. A global double-fluorescent Cre reporter mouse. Genesis 45:593-605. http://dx.doi.org/10.1002/dvg.20335.
56. Kemball CC, Harkins S, Whitmire JK, Flynn CT, Feuer R, Whitton JL. 2009. Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway. PLoS Pathog. 5:e1000618. http://dx.doi.org/10.1371/journal.ppat.1000618.
57. Furr BJ, Jordan VC. 1984. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25:127-205. http://dx.doi.org/10.1016/0163-7258 (84)90043-3.
58. van Houten N, Bouchard PE, Moraska A, Huber SA. 1991. Selection of an attenuated coxsackievirus B3 variant, using a monoclonal antibody reactive to myocyte antigen. J. Virol. 65:1286-1290.
59. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber SA. 1996. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70:7811-7818.
60. +4 in the eukaryotic consensus motif. J. Virol. 79:987-996. http://dx.doi.org/10.1128/JVI.79.2.987-996.2005.
61. Hunziker IP, Cornell CT, Whitton JL. 2007. Deletions within the 5'UTR of coxsackievirus B3: consequences for virus translation and replication. Virology 360:120-128. http://dx.doi.org/10.1016/j.virol.2006.09.041.
62. Tabor-Godwin JM, Ruller CM, Bagalso N, An N, Pagarigan RR, Harkins S, Gilbert PE, Kiosses WB, Gude NA, Cornell CT, Doran KS, Sussman MA, Whitton JL, Feuer R. 2010. A novel population of myeloid cells responding to coxsackievirus infection assists in the dissemination of virus within the neonatal CNS. J. Neurosci. 30:8676-8691. http://dx.doi.org/10.1523/JNEUROSCI.1860-10.2010.
63. Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, Yanai H, Seko Y, Shitara H, Bishop K, Yonekawa H, Tamura T, Kaisho T, Taya C, Taniguchi T, Honda K. 2008. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc. Natl. Acad. Sci. U. S. A. 105:20446-20451. http://dx.doi.org/10.1073/pnas.0810372105.
64. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. 1996. Cardiomyocyte DNA synthesis and binucleation during murine development. Am. J. Physiol. 271:H2183-H2189.
65. Banerjee I, Fuseler JW, Price RL, Borg TK, Baudino TA. 2007. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am. J. Physiol. Heart Circ. Physiol. 293:H1883-H1891. http://dx.doi.org/10.1152/ajpheart.00514.2007.
66. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, Asensio VC, Campbell IL, Whitton JL. 1998. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am. J. Pathol. 153:417-428. http://dx.doi.org/10.1016/S0002-9440 (10)65585-X.
67. Althof N, Whitton JL. 2013. Coxsackievirus B3 infects the bone marrow and diminishes the restorative capacity of erythroid and lymphoid progenitors. J. Virol. 87:2823-2834. http://dx.doi.org/10.1128/JVI.03004-12.
68. Misbah SA, Spickett GP, Ryba PC, Hockaday JM, Kroll JS, Sherwood C, Kurtz JB, Moxon ER, Chapel HM. 1992. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J. Clin. Immunol. 12:266-270. http://dx.doi.org/10.1007/BF00918150.
69. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, Pallansch MA. 1998. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36:2893-2899.
70. Martin J, Odoom K, Tuite G, Dunn G, Hopewell N, Cooper G, Fitzharris C, Butler K, Hall WW, Minor PD. 2004. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78:13839-13847. http://dx.doi.org/10.1128/JVI.78.24.13839-13847.2004.
71. 8+ T cells in lymphoid and peripheral sites of coxsackievirus B3 infection. J. Virol. 82:4331-4342. http://dx.doi.org/10.1128/JVI.02639-07.
72. Cornell CT, Kiosses WB, Harkins S, Whitton JL. 2006. Inhibition of protein trafficking by coxsackievirus B3: multiple viral proteins target a single organelle. J. Virol. 80:6637-6647. http://dx.doi.org/10.1128/JVI.02572-05.
73. Cornell CT, Kiosses WB, Harkins S, Whitton JL. 2007. Coxsackievirus B3 proteins directionally complement each other to downregulate surface major histocompatibility complex class I. J. Virol. 81:6785-6797. http://dx.doi.org/10.1128/JVI.00198-07.
74. Gorbea C, Makar KA, Pauschinger M, Pratt G, Bersola JL, Varela J, David RM, Banks L, Huang CH, Li H, Schultheiss HP, Towbin JA, Vallejo JG, Bowles NE. 2010. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J. Biol. Chem. 285:23208-23223. http://dx.doi.org/10.1074/jbc.M109.047464.
75. Hardarson HS, Baker JS, Yang Z, Purevjav E, Huang CH, Alexopoulou L, Li N, Flavell RA, Bowles NE, Vallejo JG. 2007. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am. J. Physiol. Heart Circ. Physiol. 292:H251-H258.
76. Abston ED, Coronado MJ, Bucek A, Bedja D, Shin J, Kim JB, Kim E, Gabrielson KL, Georgakopoulos D, Mitzner W, Fairweather D. 2012. Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease. Clin. Dev. Immunol. 2012:129486. http://dx.doi.org/10.1155/2012/129486.
77. Abston ED, Coronado MJ, Bucek A, Onyimba JA, Brandt JE, Frisancho JA, Kim E, Bedja D, Sung YK, Radtke AJ, Gabrielson KL, Mitzner W, Fairweather D. 2013. TLR3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection: role for IL-4. Am. J. Physiol. Regul. Integr. Comp. Physiol. 304:R267-R277. http://dx.doi.org/10.1152/ajpregu.00516.2011.
78. Wang JP, Asher DR, Chan M, Kurt-Jones EA, Finberg RW. 2007. Cutting edge: antibody-mediated TLR7-dependent recognition of viral RNA. J. Immunol. 178:3363-3367.
79. Wang JP, Cerny A, Asher DR, Kurt-Jones EA, Bronson RT, Finberg RW. 2010. MDA5 and MAVS mediate type I interferon responses to coxsackie B virus. J. Virol. 84:254-260. http://dx.doi.org/10.1128/JVI.00631-09.
80. Huhn MH, McCartney SA, Lind K, Svedin E, Colonna M, Flodstrom-Tullberg M. 2010. Melanoma differentiation-associated protein-5 (MDA-5) limits early viral replication but is not essential for the induction of type 1 interferons after coxsackievirus infection. Virology 401:42-48. http://dx.doi.org/10.1016/j.virol.2010.02.010.
81. Mukherjee A, Morosky SA, Delorme-Axford E, Dybdahl-Sissoko N, Oberste MS, Wang T, Coyne CB. 2011. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog. 7:e1001311. http://dx.doi.org/10.1371/journal.ppat.1001311.
82. Riad A, Westermann D, Zietsch C, Savvatis K, Becher PM, Bereswill S, Heimesaat MM, Lettau O, Lassner D, Dorner A, Poller W, Busch M, Felix SB, Schultheiss HP, Tschope C. 2011. TRIF is a critical survival factor in viral cardiomyopathy. J. Immunol. 186:2561-2570. http://dx.doi.org/10.4049/jimmunol.1002029.
83. Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, Chen M, Yeh WC, Akira S, Liu PP. 2005. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112:2276-2285. http://dx.doi.org/10.1161/CIRCULATIONAHA.105.536433.
84. So EY, Kang MH, Kim BS. 2006. Induction of chemokine and cytokine genes in astrocytes following infection with Theiler's murine encephalomyelitis virus is mediated by the Toll-like receptor 3. Glia 53:858-867. http://dx.doi.org/10.1002/glia.20346.
85. van Boxel-Dezaire AH, Rani MR, Stark GR. 2006. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25:361-372. http://dx.doi.org/10.1016/j.immuni.2006.08.014.
86. Stewart MJ, Smoak K, Blum MA, Sherry B. 2005. Basal and reovirusinduced β interferon (IFN-β) and IFN-β-stimulated gene expression are cell type specific in the cardiac protective response. J. Virol. 79:2979-2987. http://dx.doi.org/10.1128/JVI.79.5.2979-2987.2005.
87. Zurney J, Howard KE, Sherry B. 2007. Basal expression levels of IFNAR and Jak-STAT components are determinants of cell-type-specific differences in cardiac antiviral responses. J. Virol. 81:13668-13680. http://dx.doi.org/10.1128/JVI.01172-07.
88. Cho H, Proll SC, Szretter KJ, Katze MG, Gale M, Jr, Diamond MS. 2013. Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positivestranded RNA viruses. Nat. Med. 19:458-464. http://dx.doi.org/10.1038/nm.3108.
89. Li L, Sherry B. 2010. IFN-α expression and antiviral effects are subtypeand cell type-specific in the cardiac response to viral infection. Virology 396:59-68. http://dx.doi.org/10.1016/j.virol.2009.10.013.
90. Philip J, Xu Z, Bowles NE, Vallejo JG. 2013. Cardiac-specific overexpression of melanoma differentiation associated gene-5 protects mice from lethal viral myocarditis. Circ. Heart Fail. 6:326-334. http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.969402.
91. Xu Z, Desai M, Philip J, Sivsubramanian N, Bowles NE, Vallejo JG. 2011. Conditional transgenic expression of TIR-domain-containing adaptor-inducing interferon-β (TRIF) in the adult mouse heart is protective in acute viral myocarditis. Basic Res. Cardiol. 106:1159-1171. http://dx.doi.org/10.1007/s00395-011-0226-4.
92. Aicardi J, Goutieres F. 1984. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann. Neurol. 15:49-54. http://dx.doi.org/10.1002/ana.410150109.
93. Lebon P, Badoual J, Ponsot G, Goutieres F, Hemeury-Cukier F, Aicardi J. 1988. Intrathecal synthesis of interferon-α in infants with progressive familial encephalopathy. J. Neurol. Sci. 84:201-208. http://dx.doi.org/10.1016/0022-510X(88)90125-6.
94. Akwa Y, Hassett DE, Eloranta M-L, Sandberg K, Masliah E, Powell H, Whitton JL, Bloom FE, Campbell IL. 1998. Transgenic expression of interferon-α in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J. Immunol. 161:5016-5026.
95. Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E, Ali M, Semple C, Aicardi J, Babul-Hirji R, Baumann C, Baxter P, Bertini E, Chandler KE, Chitayat D, Cau D, Dery C, Fazzi E, Goizet C, King MD, Klepper J, Lacombe D, Lanzi G, Lyall H, Martinez-Frias ML, Mathieu M, McKeown C, Monier A, Oade Y, Quarrell OW, Rittey CD, Rogers RC, Sanchis A, Stephenson JB, Tacke U, Till M, Tolmie JL, Tomlin P, Voit T, Weschke B, Woods CG, Lebon P, Bonthron DT, Ponting CP, Jackson AP. 2006. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat. Genet. 38:910-916. http://dx.doi.org/10.1038/ng1842.
96. Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, Black DN, van Bokhoven H, Brunner HG, Hamel BC, Corry PC, Cowan FM, Frints SG, Klepper J, Livingston JH, Lynch SA, Massey RF, Meritet JF, Michaud JL, Ponsot G, Voit T, Lebon P, Bonthron DT, Jackson AP, Barnes DE, Lindahl T. 2006. Mutations in the gene encoding the 3,-5, DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 38:917-920. http://dx.doi.org/10.1038/ng1845.
97. Morita M, Stamp G, Robins P, Dulic A, Rosewell I, Hrivnak G, Daly G, Lindahl T, Barnes DE. 2004. Gene-targeted mice lacking the Trex1 (DNase III) 3, 5, DNA exonuclease develop inflammatory myocarditis. Mol. Cell. Biol. 24:6719-6727. http://dx.doi.org/10.1128/MCB.24.15.6719-6727.2004.
98. Gall A, Treuting P, Elkon KB, Loo YM, Gale M, Jr, Barber GN, Stetson DB. 2012. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 36:120-131. http://dx.doi.org/10.1016/j.immuni.2011.11.018.
99. Stetson DB, Ko JS, Heidmann T, Medzhitov R. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134:587-598. http://dx.doi.org/10.1016/j.cell.2008.06.032.